Novo Nordisk A-S

Novo Nordisk A-S

Yahoo Finance • 20 hours ago

Walmart to cover GLP-1s, insulin at no cost for workers in benefits push - report

Investing.com -- Walmart Inc (NASDAQ:WMT) plans to cover more than 250 prescription medications at no cost for its workforce, according to a staff memo from Chief People Officer Donna Morris reported by Bloomberg. The expansion includes po... Full story

Yahoo Finance • 21 hours ago

Walmart expands free drug coverage, adds healthcare benefits for workers

[Walmart Supercentre Exterior thru the Parking Lot] M. Suhail/iStock Editorial via Getty Images Walmart (WMT [https://seekingalpha.com/symbol/WMT]) plans to expand healthcare coverage for its employees next year, offering more than 250 pr... Full story

Yahoo Finance • 24 hours ago

Why A Biotech M&A Wave May Hit This Winter

Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them. Continue Reading... Full story

Yahoo Finance • 2 days ago

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S Bagsværd, Denmark, 12 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR)... Full story

Yahoo Finance • 5 days ago

Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth

Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook. The shares fell anyway, with investors fixated on pricing pressure and the quality of the beat. Then, at a strategy day in Lon... Full story

Yahoo Finance • 5 days ago

Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land

Novo Nordisk (CPSE:NOVO B) reported an FDA review update for haemophilia A therapy denecimig, including manufacturing related feedback, in October 2026. The pharmaceutical group presented new CagriSema data on brain and metabolic pathway e... Full story

Yahoo Finance • 5 days ago

Novo Nordisk stock target cut at Citi on lack of margin growth

Investing.com -- Citi Research cut its price target on Danish drugmaker Novo Nordisk to 296 Danish crowns from 310 because the company's guidance for "broadly stable" margins through 2030 leaves little room for margin growth, Citi analysts... Full story

Yahoo Finance • 6 days ago

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Apitegromab MAA resubmission includes alternate fill-finish facility in place of Catalent Indiana LLC (part of Novo Nordisk), in alignment with guidance from EMA Alternate fill-finish facility in MAA is the same site that supported Septemb... Full story

Yahoo Finance • 6 days ago

Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response

During the October 1 lightning round of Mad Money, a caller said they owned both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY). After contrasting their share-price performance, they asked which offered better upside over... Full story

Yahoo Finance • 7 days ago

Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know

In the latest trading session, Novo Nordisk (NVO) closed at $38.26, marking a +1.95% move from the previous day. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw a downswing of 0.66%, while the tech-heavy Na... Full story

Yahoo Finance • 7 days ago

European Equities Traded in US as ADRs Fall in Wednesday Trading

European equities traded in the US as American depositary receipts fell late Wednesday morning with PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 7 days ago

Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?

Novo Nordisk has seen a sharp reset in its share price over the past few years, and that shift is forcing investors to ask whether the current valuation is still supported by its earnings power. With headline-making data for semaglutide ac... Full story

Yahoo Finance • 8 days ago

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 9 days ago

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

DelveInsight Business Research LLP The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early d... Full story

Yahoo Finance • 9 days ago

CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium

Four sessions across two days focusing on key drug discovery and development application areas oforgan-on-a-chip technologies Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, includ... Full story

Yahoo Finance • 9 days ago

Novo Looks Beyond GLP-1s as Competition Intensifies

In the past, Novo Nordisk A/S (NYSE:NVO) has been a dominant player in diabetes and obesity treatments, with Ozempic and Wegovy driving a significant portion of the company's recent growth. Those drugs transformed the company into one of t... Full story

Yahoo Finance • 9 days ago

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) a... Full story

Yahoo Finance • 13 days ago

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Novo Nordisk A/S Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy®(injectable semaglutide 7.2 and 2.4 mg) treatment. 9 in 1... Full story

Yahoo Finance • 13 days ago

Regeneron drug said to cut muscle loss when combined with Novo's semaglutide

[Doctor doing research in lab during COVID-19] Morsa Images * An experimental weight-loss drug being developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) used in combination with Novo Nordisk's (NVO [https://seekingalpha... Full story

Yahoo Finance • 14 days ago

Pharmaceutical industry lobbying group names new CEO, Eric Cantor

[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and... Full story